Is One Immunotherapy for Lung Cancer Better Than the Rest?

The final analysis of the phase 2/3 CCTG IND.227/KEYNOTE-483 trial identifies a statistically significant survival benefit with pembrolizumab and chemotherapy vs chemotherapy alone in the first-line setting for patients with unresectable advanced or metastatic malignant pleural mesothelioma.

ONCOLOGY spoke with Eric Ko, MD, PhD, who recently published a review article with his colleagues on strategies for combining radiation therapy with immunotherapy for the treatment of non–small-cell lung cancer.

Data from a retrospective study suggests that stereotactic body radiotherapy may be a suitable alternative to surgical resection for patients with primary lung neuroendocrine tumors, according to an expert from Moffitt Cancer Center.

Smoking cessation and relapse prevention expert Alan Blum, MD, discusses how oncologists and other clinicians can and should play a larger role in tobacco control.

An expanded indication for pafolacianine as an imaging agent for patients with lung cancer has been approved by the FDA based on findings from the phase 3 ELUCIDATE trial.

An expert from NYU Langone in New York City recently discussed the strengths and limitations of the oral tyrosine kinase inhibitor mobocertinib in platinum-pretreated patients with EGFR exon 20 insertion+ metastatic non-small cell lung cancer.